Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Lists
Only you see this
Abstract
In this comprehensive evaluation, pretreatment total circulating VEGF-A was prognostic for outcome in metastatic colorectal, lung, and renal cell cancers, but it was not predictive for bevacizumab-based treatment benefit.
BibTeX
@inproceedings{hegde2012predictive,
author = {Priti S. Hegde and Adrian M. Jubb and Dafeng Chen and Nicole F. Li and Yong Meng and Coen Bernaards and Rebecca Elliott and Stefan Scherer and Daniel S. Chen},
title = {{Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab}},
booktitle = {Clinical},
year = {2012},
doi = {10.1158/1078-0432.ccr-12-2535},
}Loading related content...